Inflammatory Colitis - A Recap

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 34

MANAGEMENT OF ACUTE

SEVERE ULCERATIVE COLITIS

Dr. Anahita Sharma


ST4 Gastroenterology, Royal Blackburn Hospital
• To generate a differential
diagnosis with regards to the
patient presenting with
acute/acute-on-chronic
diarrhoea.
• To be able to use criteria to
determine the severity of an acute
LEARNING OBJECTIVES
flare of ulcerative colitis as well
as prognosticate response to
steroids.
• To understand how to initiate
appropriate investigations and
treatment for an acute severe flare
of colitis.
• A 36-year old lady presents to A&E
with a 6-week history of increased
stool frequency, associated with
rectal bleeding and mucoid stools.
• She complains of diffuse and
spasmodic abdominal pain associated
with the diarrhoea.
• She states she opens her bowels 6–7
times on each day; prior to last
month, she normally opened them
twice a day.
• She has no recent travel history or
history of trying new foods.
EXAMINATION (1)

• She appears dehydrated and looks to be in pain.


• Her observations are as follows:
• HR: 105, regular
• BP 130/50
• RR: 18
• T: 37.4°C
• GCS = 15
• Has passed urine whilst in the department
• SpO2: 99% on room air
EXAMINATION (2)

• On examination of her abdomen, she is markedly


tender over the entire abdomen, but more so on the
left side.
• Her abdomen is distended but there are no signs of
peritonism.
• She cannot tolerate a per rectal examination.
BLOOD TESTS 💉

• FBC • LFTs, amylase


• Hb 114 g/L • Normal
• WCC 14.0 x 109/L (↑) • CRP
• Platelets 450 x 109/L • 45 mg/dL (↑)
• U&Es • Lactate
• Normal • 2.7 mM (↑)
• What are your working diagnoses?
• Flare-up of ulcerative colitis (↑ ↑
probability)
• Infectious colitis (↓ probability)
• Crohn's colitis
QUESTIONS (1) • Diverticulitis
• Ischaemic colitis
• Radiation-induced colitis
• Vasculitis
• Drug-induced colitis [which drugs?]
• Highest prevalence in North America
and Northern Europe, with a
prevalence of 156-291 cases per
100,000 people
• Bi-modal pattern of incidence (mainly
occurs at 15-30 years with a smaller
ULCERATIVE peak at 50-70 years)
COLITIS • Inflammation starts in rectum and
extends proximally
• Crypt disrtortion, crypt abscesses and
plasma-lymphocytoid cell infiltrate in
lamina propria on biopsy
• Risk factors: genetics, previous enteric
infections, environmental factors
INVESTIGATIONS

• What specific imaging would


you initially request?
• Abdominal X-ray – to exclude
toxic megacolon
• CT abdomen/pelvis – if
suspicion of surgical abdomen
(abscess or perforation), toxic
megacolon
• Any other investigations?
Mayo Scoring:
(A) Score 0=normal; endoscopic remission.
(B) Score 1=mild; erythema, decreased
vascular pattern, mild friability. (C) Score
2=moderate; marked erythema, absent
vascular pattern, friability, erosions.
(D) Score 3=severe; spontaneous bleeding,
ulceration.
HOW DO YOU
P R O G N O S T I C AT E / D E T E R M I N E
SEVERITY OF THE FLARE?

• Truelove & Witts’ criteria


• Faecal calprotectin (cut-off of
1922.5/g, 87% of patients
underwent colectomy over 1.1
years)
• Biochemical and endoscopic
parameters – CRP >50, albumin
<30 and increased endoscopic
severity predict non-response to
steroids
TRUELOVE &
WITTS’
CRITERIA

N.B. Patients
with IBD will
not always
mount a ‘high’
CRP response
TREATMENT

• How else would you manage this patient?


• High-dose steroids – IV hydrocortisone 100 mg QDS
• PPI co-prescription not indicated unless ↑ risk of peptic ulcer disease/GI bleed
• Co-prescribe with osteoprotection [consider DEXA if frequent steroid courses]
• Send stool cultures MC&S, incl. C. difficile toxin test [CDI is associated with ↑
mortality] & faecal calprotectin
• IV fluids
• IV antibiotics, if indicated
• Stool chart (give to patient to record output)
• IP flexi-sig [unprepped]
• VTE prophylaxis (pro-thrombotic state ++)
MANAGEMENT –
GENERAL MEASURES

• How else would you manage


this patient?
• Send biologic screen [HIV, hep
B/C, VZV, TB quantiferon,
TPMT]
• Re-assess progress on day 3
according to Travis Criteria
Response is defined as a sustained score of
<10 on the modified Truelove & Witts
index

Non-response to steroids at 72 hours is


associated with a high colectomy rate
ASSESSING
RESPONSE • Travis Criteria – if fulfilled, 85% probability of
undergoing emergency colectomy
• If stool frequency >8, or 3-8 stools and CRP >45

Rescue therapy is indicated in non-


responders
TREATMENT ESCALATION

Ciclosporin (2mg/kg per


day by continuous As per UK-
Infliximab (5mg/kg on infusion for up to 7 CONSTRUCT RCT, no
days 0, 14 and 42) days, then oral therapy difference in outcomes
bd 5.5mg/kg for 12 for these 2 treatments
weeks)

Can be used as a bridge


Accelerated dosing may to thiopurine or
Often agent of choice For patients who are
reduce short-term vedolizumab therapy in
due to ease/familiarity TNF-naïve
colectomy rates patients who are naïve
to thiopurines
IgG1 monoclonal antibody which targets TNF-α

Standard dose: 5 mg/kg IV at weeks 0, 2, 6 then 8-


weekly

Accelerated dose: 5 mg/kg IV at weeks 0, 1, 3 then


INFLIXIMAB 8-weekly [“antigen sink”, faecal infliximab loss]

Contraindications:
• Congestive cardiac failure [NYHA III/IV]
• Demyelinating disease
• Sepsis or active infection
• Active tuberculosis
SURGICAL OPTIONS

• Emergency surgery is associated with higher


mortality, morbidity and postoperative infectious
complications
↑ LIKELIHOOD OF NEED FOR SURGERY

• Stool frequency > 8/d.


• Pyrexia
• Tachycardia
• Colonic dilatation
• Low albumin / anaemia /
thrombocytosis / raised CRP >45
TOXIC
MEGACOLON
MANAGEMENT – MILD-
MODERATE FLARES

• Remission/management of mild-
moderate colitis:
• Topical therapies – 5-aminosalicylates
(mesalazine) or corticosteroid
suppositories
• Oral therapies – 5-aminosalicylates
(avoid steroids due to long-term
effects)
• AZT/mercaptopurine if refractory to 5-
ASAs
• Consideration of biologic therapy (e.g.
infliximab)
• Always define the extent of
inflammatory bowel disease (i.e.
pancolitis, right- or left-sided, ileo-
caecal, perianal) as this influences
management.
• Steroids may not always be
CROHN’S DISEASE appropriate, particularly if there is
– ADDITIONAL evidence of surgical pathology e.g.
CONSIDERATIONS
perforation.
• In fistulating Crohn’s disease,
further imaging with CT and MRI
of pelvis and rectum may be
required, with possible involvement
of a colorectal surgeon. IBD MDT
involvement is essential.
ELHT
GUIDELINES
(1)
ELHT GUIDELINES
(2)
ELHT GUIDELINES (3)
ELHT GUIDELINES
(4)
SOURCES

• Conley TE, Fiske J, Subramanian S How to manage: acute severe colitis


Frontline Gastroenterology 2022;13:64-72.
• Ordas IE et al. Ulcerative Colitis – Seminar. Lancet 2012; 380: 1606-19.
• ELHT Guidelines

You might also like